AMD Clinical Trials

49 recruitingLast updated: July 25, 2026

There are 49 actively recruiting amd clinical trials across 28 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4. Top locations include Austin, Texas, United States, Sacramento, California, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


AMD Trials at a Glance

49 actively recruiting trials for amd are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Austin, Sacramento, and Dallas. Lead sponsors running amd studies include Adverum Biotechnologies, Inc., AbbVie, and Fondazione G.B. Bietti, IRCCS.

Treatments under study

About AMD Clinical Trials

Looking for clinical trials for AMD? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AMD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AMD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Not Applicable

Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital4,300 enrolled1 locationNCT07069647
Recruiting
Not Applicable

Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)
National Taiwan University Hospital1,000 enrolled1 locationNCT06843499
Recruiting
Phase 2

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled53 locationsNCT06659445
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT07482176
Recruiting
Phase 3

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled29 locationsNCT07614776
Recruiting
Phase 3

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled218 locationsNCT06541704
Recruiting
Not Applicable

MacuTherm Performance Study in Patients With iAMD

Intermediate AMD
OD-OS MacuTherm GmbH240 enrolled4 locationsNCT07607496
Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Neovascular Age-Related Macular Degeneration (nAMD)
Ocular Therapeutix, Inc.850 enrolled8 locationsNCT07516132
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting
Phase 2

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting

Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context

Age related macular degeneration (AMD)
Centre Hospitalier Universitaire, Amiens600 enrolled1 locationNCT03577041
Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital300 enrolled27 locationsNCT07640997
Recruiting
Phase 2

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.15 enrolled4 locationsNCT07630649
Recruiting
Not Applicable

Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment

Age related macular degeneration (AMD)Diabetic Retinopathy (DR)Retinal Detachment
Fondazione G.B. Bietti, IRCCS260 enrolled1 locationNCT07500324
Recruiting

Visual Rehabilitation and Depression in Visually Impaired Patients With AMD

AnxietyDepression DisordersAMD - Age-Related Macular Degeneration
Fondazione G.B. Bietti, IRCCS22 enrolled1 locationNCT06906003
Recruiting
Not Applicable

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular DegenerationAge-Related Macular DegenerationIntermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD100 enrolled13 locationsNCT06662162
Recruiting
Phase 3

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

wet age related macular degenerationAMDnAMD+3 more
AbbVie714 enrolled181 locationsNCT05407636
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759